plus

GIGABYTE Launches Z890 Plus Series Motherboards Supporting Intel Core Ultra 200S Plus Series Processors and CQDIMM Technology

TAIPEI, March 11, 2026 /PRNewswire/ -- GIGABYTE, the world's leading computer brand, introduces the Z890 Plus Series Motherboards engineered to…

6 days ago

Paingone Plus TENS Pen Featured in 2026 Consumer Report Examining FDA Clearance Status, TENS Pain Therapy Research, and Portable Pain Relief Device Verification

Tukwila, WA, March 05, 2026 (GLOBE NEWSWIRE) -- This report examines publicly available marketing statements and published research literature. Where…

2 weeks ago

Landmark Study Demonstrates Sustained Clinical Benefits of Flexitouch Plus as First-Line Therapy in Treating Head and Neck Cancer-Related Lymphedema

October 28, 2025 16:05 ET  | Source: Tactile Systems Technology, Inc. MINNEAPOLIS, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Tactile Systems…

5 months ago

DFSK Celebrates 20 Years of Global Expansion with E5 PLUS, the First Overseas New Energy Strategic Model, Rolls Off the Production Line

CHONGQING, China, Oct. 22, 2025 /PRNewswire/ -- On October 22, 2025, at the Chongqing SERES Shuangfu Plant, DFSK's first overseas new…

5 months ago

IO Biotech Presents Phase 3 Results for Cylembio plus KEYTRUDA (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025

October 20, 2025 02:30 ET  | Source: IO Biotech Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression…

5 months ago

Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025

October 19, 2025 08:00 ET  | Source: Replimune, Inc. WOBURN, Mass., Oct. 19, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc.…

5 months ago

Sandstone Easydrip Plus Pen Needles Debut in Turkey — PatentProtected Hexagonal Hub for Comfort and Control

Large‑platform hexagonal hub (Hextra Tech) offers superior stability and ease of grip; ISO 13485 & CE certified; launched by a leading…

5 months ago

FDA approves Roches Tecentriq plus lurbinectedin as first-line maintenance therapy for extensive-stage small cell lung cancer

Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase…

6 months ago

NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Nave or Resistant R/M-HNSCC

Treatment remained well-tolerated with consistent injection feasibility in 103 heavily pre-treated patients with R/M-HNSCC naïve or resistant to anti-PD-163% (26/41)…

6 months ago